Advice
in the absence of a submission from the holder of the marketing authorisation
eltrombopag olamine (Revolade®) is not recommended for use within NHS Scotland.
Indication under review: Treatment in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice49KB (PDF)
Medicine details
- Medicine name:
- eltrombopag olamine (Revolade)
- SMC ID:
- 1164/16
- Indication:
- treatment in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 June 2016